Evidence map›Paper›PMID 36524007›Full record

ArticleACS pharmacology & translational science2022

In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1

Hayley M Green, David B Finlay, Ruth A Ross, Iain R Greig, Stephen B Duffull, Michelle Glass

Open access · greenAbstract read
In one paragraph

Article in ACS pharmacology & translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Hayley M GreenDepartment of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin9054, New Zealand.
David B FinlayDepartment of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin9054, New Zealand.ORCID https://orcid.org/0000-0002-3160-2931
Ruth A RossDepartment of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, TorontoM5S 1A8, Canada.
Iain R GreigSchool of Medicine, Medical Sciences and Nutrition, University of Aberdeen, AberdeenAB24 3FX, U.K.
Stephen B DuffullOtago Pharmacometrics Group, School of Pharmacy, University of Otago, Dunedin9016, New Zealand.
Michelle GlassDepartment of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin9054, New Zealand.ORCID https://orcid.org/0000-0002-5997-6898
University of Otago · NZUniversity of Aberdeen · GBUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Orthosteric activation of CB

Identifiers

PMID36524007
PMCPMC9745890
OpenAlexW4309670946

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.